Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

24.14 -0.40 (-1.65%)
Streaming Delayed Price Updated: 3:58 PM EDT, Jun 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 425,542
Open 24.32
Bid (Size) 24.13 (1,500)
Ask (Size) 24.14 (1,200)
Prev. Close 24.54
Today's Range 24.06 - 24.55
52wk Range 11.32 - 29.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire

Performance

YTD
-9.3%
-9.3%
1 Month
-9.9%
-9.9%
3 Month
+3.5%
+3.5%
6 Month
-7.3%
-7.3%
1 Year
+107.3%
+107.3%

More News

Read More
News headline image
Zymeworks Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Zymeworks (NASDAQ:ZYME) Misses Q1 Estimates But August PDUFA Date for Zanidatamab Offers Key Regulatory Catalyst ↗
Via Chartmill
Zymeworks Inc (NASDAQ:ZYME) Posts Wider Q4 Loss Despite Strategic Progress and Royalty Deal ↗
Via Chartmill
News headline image
Zymeworks (ZYME) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
Via The Motley Fool
News headline image
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
Topics Stocks
News headline image
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
From Zymeworks Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Zymeworks Inc. - Common Stock publicly traded?
Yes, Zymeworks Inc. - Common Stock is publicly traded.
What exchange does Zymeworks Inc. - Common Stock trade on?
Zymeworks Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Zymeworks Inc. - Common Stock?
The ticker symbol for Zymeworks Inc. - Common Stock is ZYME on the Nasdaq Stock Market
What is the current price of Zymeworks Inc. - Common Stock?
The current price of Zymeworks Inc. - Common Stock is 24.14
When was Zymeworks Inc. - Common Stock last traded?
The last trade of Zymeworks Inc. - Common Stock was at 06/02/26 03:58 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.